INTRODUCTION: The purpose of the EANM Dosimetry Committee Series on "Standard Operational Procedures for Pre-therapeutic Dosimetry" (SOP) is to provide advice to scientists and clinicians on how to perform pre-therapeutic and/or therapeutic patient-specific absorbed dose assessments. MATERIAL AND METHODS: This particular SOP gives advice on how to tailor the therapeutic activity to be administered for systemic treatment of differentiated thyroid cancer (DTC) such that the absorbed dose to the blood does not exceed 2 Gy (a widely accepted limit for bone marrow toxicity). The methodology of blood-based dosimetry has been developed in the 1960s and refined in a series of international multi-centre trials in the framework of the introduction of new diagnostic and therapeutic tools, e.g. recombinant human thyroid-stimulating hormone in the management of DTC. CONCLUSION: The intention is to guide the user through a series of measurements and calculations which the authors consider to be the best and most reproducible way at present.
INTRODUCTION: The purpose of the EANM Dosimetry Committee Series on "Standard Operational Procedures for Pre-therapeutic Dosimetry" (SOP) is to provide advice to scientists and clinicians on how to perform pre-therapeutic and/or therapeutic patient-specific absorbed dose assessments. MATERIAL AND METHODS: This particular SOP gives advice on how to tailor the therapeutic activity to be administered for systemic treatment of differentiated thyroid cancer (DTC) such that the absorbed dose to the blood does not exceed 2 Gy (a widely accepted limit for bone marrow toxicity). The methodology of blood-based dosimetry has been developed in the 1960s and refined in a series of international multi-centre trials in the framework of the introduction of new diagnostic and therapeutic tools, e.g. recombinant human thyroid-stimulating hormone in the management of DTC. CONCLUSION: The intention is to guide the user through a series of measurements and calculations which the authors consider to be the best and most reproducible way at present.
Authors: Katherine S Kolbert; Keith S Pentlow; Joel R Pearson; Arif Sheikh; Ronald D Finn; John L Humm; Steven M Larson Journal: J Nucl Med Date: 2007-01 Impact factor: 10.057
Authors: R Michael Tuttle; Rebecca Leboeuf; Richard J Robbins; Rebecca Qualey; Keith Pentlow; Steven M Larson; Chee Y Chan Journal: J Nucl Med Date: 2006-10 Impact factor: 10.057
Authors: Heribert Hänscheid; Michael Lassmann; Markus Luster; Stephen R Thomas; Furio Pacini; Claudia Ceccarelli; Paul W Ladenson; Richard L Wahl; Martin Schlumberger; Marcel Ricard; Al Driedger; Richard T Kloos; Steven I Sherman; Bryan R Haugen; Vincent Carriere; Carine Corone; Christoph Reiners Journal: J Nucl Med Date: 2006-04 Impact factor: 10.057
Authors: Hong Song; Bin He; Andrew Prideaux; Yong Du; Eric Frey; Wayne Kasecamp; Paul W Ladenson; Richard L Wahl; George Sgouros Journal: J Nucl Med Date: 2006-12 Impact factor: 10.057
Authors: Sarah J Chittenden; Brenda E Pratt; Kay Pomeroy; Peter Black; Clive Long; Nicholas Smith; Susan E Buckley; Frank H Saran; Glenn D Flux Journal: Cancer Biother Radiopharm Date: 2007-04 Impact factor: 3.099
Authors: Frederik A Verburg; Markus Dietlein; Michael Lassmann; Markus Luster; Christoph Reiners Journal: Eur J Nucl Med Mol Imaging Date: 2009-03 Impact factor: 9.236
Authors: Frederik A Verburg; Alexander Heinzel; Heribert Hänscheid; Felix M Mottaghy; Markus Luster; Luca Giovanella Journal: Eur J Nucl Med Mol Imaging Date: 2013-11-06 Impact factor: 9.236
Authors: Gary L Francis; Steven G Waguespack; Andrew J Bauer; Peter Angelos; Salvatore Benvenga; Janete M Cerutti; Catherine A Dinauer; Jill Hamilton; Ian D Hay; Markus Luster; Marguerite T Parisi; Marianna Rachmiel; Geoffrey B Thompson; Shunichi Yamashita Journal: Thyroid Date: 2015-07 Impact factor: 6.568
Authors: Sander M Bison; Mark W Konijnenberg; Marleen Melis; Stefan E Pool; Monique R Bernsen; Jaap J M Teunissen; Dik J Kwekkeboom; Marion de Jong Journal: Clin Transl Imaging Date: 2014-03-05
Authors: Frederik A Verburg; Markus Luster; Luca Giovanella; Michael Lassmann; Carlo Chiesa; Nicolas Chouin; Glenn Flux Journal: Eur J Nucl Med Mol Imaging Date: 2017-02-16 Impact factor: 9.236
Authors: M Luster; S E Clarke; M Dietlein; M Lassmann; P Lind; W J G Oyen; J Tennvall; E Bombardieri Journal: Eur J Nucl Med Mol Imaging Date: 2008-10 Impact factor: 9.236